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Abstract
With the advent of genome-wide association (GWA) studies, researchers are hoping that reliable genetic association of
common human complex diseases/traits can be detected. Currently, there is an increasing enthusiasm about GWA and a
number of GWA studies have been published. In the field a common practice is that replication should be used as the gold
standard to validate an association finding. In this article, based on empirical and theoretical data, we emphasize that
replication of GWA findings can be quite difficult, and should not always be expected, even when true variants are
identified. The probability of replication becomes smaller with the increasing number of independent GWA studies if the
power of individual replication studies is less than 100% (which is usually the case), and even a finding that is replicated may
not necessarily be true. We argue that the field may have unreasonably high expectations on success of replication. We also
wish to raise the question whether it is sufficient or necessary to treat replication as the ultimate and gold standard for
defining true variants. We finally discuss the usefulness of integrating evidence from multiple levels/sources such as genetic
epidemiological studies (at the DNA level), gene expression studies (at the RNA level), proteomics (at the protein level), and
follow-up molecular and cellular studies for eventual validation and illumination of the functional relevance of the genes
uncovered.
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Introduction
With the advent of genome-wide association (GWA) studies, it is
anticipated that major susceptibility variants for common human
diseases/traits can be detected [1]. With successful application of
GWA studies first appearing in 2005, to date more than 190 GWA
studies have been published, reporting more than 410 SNPs
showing strong evidences of association with various human
complex diseases/traits, such as obesity, diabetes, coronary heart
diseases, asthma, cancers, mental illness, and osteoporosis (a
catalog of published GWA studies is summarized at the
National Human Genome Research Institute (NHGRI) website
at www.genome.gov/26525384). Some GWA findings were
confirmed in subsequent independent replication studies. With
the belief that replication should be used as a gold standard in
high quality publications, the NCI-NHGRI Working Group
proposed suggestions in the June 2007 issue of Nature on what
constitutes replication of a genotype-phenotype association,
and how best to achieve this [2]. A commonly used review
criterion for a GWA study is whether it is accompanied by
internal (e.g., within consortium) or external (independent studies
by other research groups in different populations) replication
evidence.
In this article, based on empirical and theoretical data, we show
that, like conventional linkage scan and candidate gene association
studies, GWA results are also going to be very difficult to replicate
even for powerful, well-designed studies. We demonstrate that 1)
the probability of replication becomes smaller as the number of
independent GWA studies increases if the power of individual
replication studies is less than 100% (which is usually the case), and
2) statistically replicated findings are not necessarily true, although
replication lessens the likelihood of the initial finding being false.
We question whether it is necessary or sufficient to regard
replication as the gold standard for defining a true susceptibility
variant. We lastly discuss the usefulness of integrating evidence
from multiple level/sources such as genetic epidemiology,
functional genomics, proteomics, and molecular and cellular
functional studies.
Results
1) GWA Results Are Inherently Difficult to Replicate
In GWA studies, a finding is considered to be ‘‘replicated’’ if
and only if there is an initial finding which did appropriately
control for multiple testing with strong control of the family-wise
type I error rate (FWER) and in a second independent sample this
finding is re-detected in a confirmatory hypothesis testing setting
[2]. In the following we show that the probability of replicating
GWA results is inherently low. We also discuss some confounding
factors that may further exacerbate the situation.
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4037a) The probability of replicating GWA results is
inherently low. For simplicity, we assume an ideal situation
in which a gene-phenotype association exists and is identified by
the initial GWA. We then examine the probability of replicating
the association under three slightly different scenarios: 1) the initial
GWA findings are followed by several subsequent independent
replication studies (either GWA or focused regional analyses); 2)
two or more independent GWA studies are conducted
simultaneously; and 3) a mixture of N GWA (N,3–4) and R
replication studies (R.5–6) on a smaller number of markers.
The power calculation in each scenario was performed using
the ‘‘Genetic Power Calculator’’ which is public available
(http://pngu.mgh.harvard.edu/,purcell/gpc/). All the power
calculations in the ‘‘Genetic Power Calculator’’ are based upon
formula derived in Sham et al. [3].
Scenario one. Due to polygenic inheritance of complex
diseases/traits, the chance of replicating a susceptibility variant is
much lower than that of initially detecting it. This is because in a
GWA study designed to identify quantitative trait loci (QTLs), it is
usually easy to detect one of the QTLs, even if the effect of the
detected QTL is small and the statistical power of the study is low.
As a numerical demonstration, suppose there are 20 QTLs
underlie a complex trait, each explaining 1% phenotypic
variation. Assuming an ideal situation that the QTL effect size
of 0.01, the QTL allele frequency of 0.20, the marker allele
frequency of 0.30, linkage disequilibrium (LD) between the QTL
and the marker of 0.80 (D9), and the significance level
a=5.0610
27, a GWA study with a large sample of 4,000
unrelated subjects (commonly used in current GWA studies) may
only have ,10% power to detect a specific QTL among these 20
QTLs, but this GWA study has a much higher power of ,88%
(12(1–10%)
20) to detect at least one of the QTLs.
However, the probability of replicating the specific QTL detected
in the initial GWA will generally be low in subsequent replication
studies. For example, under the same ideal situation assumed
above, an independent replication study with a sample size of
4,000 unrelated subjects will only have ,49% power to replicate
the initial finding at a much less stringent significance level of
a=10
24. Therefore, the specific QTL identified in the initial GWA
can be replicated unless a much larger sample with much higher
power is used. In practice it should be noted that the actual effect
of the identified variant in an initial study is usually overestimated,
a phenomenon called winner’s curse [4–6]. Thus, the actual
required sample size for replication is even larger than the one
estimated based on the effect size reported in the initial discovery
study.
Scenario two. We assume that two independent GWA
studies are performed simultaneously. The likelihood that a
specific susceptibility variant can be found by both studies (i.e.,
replicated by each other) is:
PA 1,A2jz ðÞ ~PA 1jz ðÞ :PA 2jz ðÞ ~power A1 ðÞ :power A2 ðÞð 1Þ
where P(A1, A2|+), the probability of detecting the susceptibility
variant by both studies, is the product of the power of each study
[denoted as power(A1) and power(A2)]. When both studies have 10%
power, the probability of detecting the same variant is as low as
1% (i.e., 10%610%). This probability is increased to 64% when
both studies have much higher power of 80%. However, when one
study has a high power of 80% and the other has low power of
10%, the probability of detecting the same variant is still as low as
8% (10%680%).
In the case of more than two independent GWA studies,
consistent replication across studies becomes increasingly
challenging and the probability of replication becomes diminish-
ingly small unless each study has power close to 100%. Assuming
that N independent GWA studies are performed, the probability of
replicating a specific susceptibility variant by all the studies is
PA 1,...,Anjz ðÞ ~ P
n
i~1
power Ai ð2Þ
It can be seen that the likelihood of consistent replication by N
individual studies depend on the statistical power of each study,
and particularly, on the study of the lowest power. As the number
of individual, independent studies increases, there is a dramatic
decrease in the probability that the same variant will be consistently
significant in all of those studies (shown in Figure 1).
A possible illustration for this scenario is four large, recently
published GWA studies for type 2 diabetes [7–10]. The first
published one was performed in a French case-control cohort [10].
The other three were performed, respectively, by the Finland-
United States Investigation on NIDDM Genetics (FUSION) team
[9], the Diabetes Genetics Initiative [8], and the Wellcome Trust
Case-Control Consortium [7]. Each GWA identified a number of
loci that may confer type 2 diabetes risk. However, only a limited
few loci (e.g., TCF7L2 and SLC30A8) showed significant
associations across ALL the four studies. Notably, neither of these
loci achieved a genome-wide significance level (a P value of 10
27
[11]) in all the four studies.
Scenario three. This scenario represents a hybrid of scenarios
one and two. We assume that there are N independent GWA and
R replication studies. Without loss of generality, let’s consider a
situation, where two independent GWA (N=2) are followed by six
replication studies (R=6) on a smaller number of markers.
Suppose there are 20 QTLs, each explaining 1% phenotypic
variance. As shown in Scenario one, under an ideal situation, a
GWA study with a sample size of 4,000 may have only ,10%
power to detect a specific QTL among these 20 QTLs, but the
study may have a high power of ,88% (1–(1–10%)
20) to detect at
least one of these 20 QTLs. The probability that the same QTL can
be identified by both initial GWA studies is only ,8.8%
(10%688%). To achieve 80% power to replicate this association
in follow-up studies (assuming D9=0.80, QTL allele frequency
of 0.20, marker allele frequency of 0.30, a level of 10
24,n o
Figure 1. The probability of replication in different numbers of
independent GWA studies. We assume all the studies have the same
power (0.90, 0.80, and 0.70) to detect a specific genotype-phenotype
association.
doi:10.1371/journal.pone.0004037.g001
GWA Replication
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sample of at least 6,000 subjects is needed. Even if replication is
achieved, there is still a possibility that the finding is false positive
(shown below in section ‘‘Are Replicated GWA Findings Always
True?’’).
b) Influence of LD and allele frequency difference. GWA
is an ‘‘indirect’’ approach testing association between markers and
diseases/traits of interest. Thus, not only the frequency of
susceptibility variants but also the markers may affect the
likelihood of detecting/replicating associations. The influence of
LD and allele frequency difference on association studies has been
demonstrated for diseases [12–14], but their quantitative effects on
quantitative traits (e.g., BMI) have not been studied. To further
illustrate the principles for quantitative traits, we show how these
population-specific characteristics (i.e., marker and susceptibility
allele frequencies, and LD strength) may affect study power. We
consider this in terms of marker effect size, which we can estimate
in practical studies.
Let’s consider a diallelic QTL (Q/q) and a diallelic marker
(M/m), with frequencies of PQ, Pq, PM, and Pm, respectively.
Assuming LD (D9) between the QTL and the marker ranges from
0.1 to 1.0, we can calculate the marker effect size (see Appendix
S1 for detail). Figure 2 shows how the measured marker effect
sizes are influenced by frequencies of the QTL and marker and
LD between them. It can be seen that the power of a GWA is
greatest when allele frequencies of the QTL and the marker
match. Discrepancies in allele frequency between the QTL and
the marker may reduce power, often dramatically as the
magnitude of this power reduction increases as the discrepancy
in allele frequency increases. When susceptibility variant and
marker allele frequencies match, the marker effect size is
approximately proportional to the QTL effect size multiplied by
the D9 value between the two loci. Since allele frequencies of the
QTLs and markers and LD strength may vary across populations
[15–17], the power of GWA studies in different study populations
may have different power to detect a QTL, even if the sample sizes
are the same. A situation that may make replication even more
difficult is long-range LD or cross-chromosome LD which may
exist in the human genome [18]. Intuitively, such long range LD
may have greater variation between different populations.
c) Confounding factors. Diversity in subject ascertainment
and study design across studies may significantly impact GWA
replication [11]. In addition, confounding factors, such as
population stratification, genetic heterogeneity, environmental
factors, and interactions between genetic and environmental
factors (which may vary with different populations and
environments), may reduce the chance of GWA replication.
Most of these factors have been well recognized and evaluated in
association studies for candidate genes [19]. Here we only briefly
review these factors with regard to GWA studies.
Population stratification/admixture may mask, change or even
result in apparently reversed genetic effect of genes underlying
complex disease/traits. The available methods addressing/
controlling this problem may have potential limitations [20–23].
For example, the Genome Control method [20] assumes that the
degree of population differentiation is the same throughout the
human genome, which may not the case. The performance of
the Structured Association method [23] is highly dependent upon
the amount and informativeness of ancestry informative markers
(AIMs) [24], and the accuracy of inferred individual ancestry is
sensitive to the number of pre-assigned subpopulations, which may
not always be satisfactorily resolved [25]. In addition, the use of
the Structured Association method for GWA studies is limited
due to its intensive computational cost for large data sets.
Principal component analysis [22] is a recently developed method
specifically for GWA; however, it may lead to incomplete
stratification correction when the number of markers is less than
20,000 [26].
Genetic heterogeneity is a common phenomenon in human
diseases. A disease could be caused by different susceptibility
variants in different populations. For a specific susceptibility
variant, there may also exist genuine diversity of its genetic effect
in different populations [27]. The allele frequency of a
susceptibility variant could be different across different popula-
tions. Since the population genetic effect of a susceptibility variant
depends on its allele frequency (Figure 2), it should not be
surprising that a significant association identified in one population
cannot be found in another. A recent study estimated the required
sample size to replicate an association finding with different
amounts of between-study heterogeneity [28]. The authors
concluded that: 1) if between-study heterogeneity reaches certain
thresholds, it may not be practically possible to consistently
replicate some true associations, no matter how large the studies
are, and 2) replication sample sizes of 40,000 subjects or even
larger are essential for generating sufficient power to replicate an
association of small or modest effect size [28].
Studies have shown that LD patterns vary substantially among
different populations [29–32]. This differential LD (or LD
heterogeneity) may cause nonreplication of GWA findings across
studies in different populations[27]. LD heterogeneity may exist
even in populations of the same ethnic group such as Caucasians
of European ancestry [30,33,34], although data accumulated
from recent GWA studies [35–37] tend to show that, between
Caucasian populations, the LD is not very heterogeneous. The
diverse intermarker LD may affect the probability of replicating a
gene or region and this should be considered when designing a
replication study, especially with regard to marker-selection
strategy. Clarke et al. [38] showed that when a region of high
intermarker LD is tested to replicate an initial finding that is only
weak association with a disease, the ‘‘local’’ approach that involves
both the originally significant markers and others in the same
regions is a good strategy. Otherwise, the most powerful and
efficient strategy for replication involves testing only the initially
identified variants [38].
Figure 2. How marker effect size (y-axis) is determined by QTL
effect size, marker allele frequency (MAF) and QTL allele
frequency, and extent of LD between marker and QTL. We
assume the QTL is under additive inheritance with MAF of 0.10 and
effect size of 0.05 and the LD is measured by D9 (x-axis).
doi:10.1371/journal.pone.0004037.g002
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different exposures to environmental factors. For example,
lifestyles such as diet, smoking, alcohol drinking, nutritional
status, and exercises may have significant influence on human
body fat (a focal phenotype for obesity research). These factors are
sometimes difficult to be assessed and quantified accurately and
their actual influence on body fat variation might not be
judiciously accounted for in statistical analyses, although there is
a debate on whether the statistical adjustment for environmental
factors is necessary [39].
2) Are Replicated GWA Findings Always True?
In the field a common practice is that a significant GWA finding
is considered to be ‘‘true’’ if replicated by several subsequent
studies (not necessarily all). However, are replicated GWA findings
always true? Some Bayesian based approaches (such as positive
predictive value (PPV) to be discussed below) or complementary
approaches (such as Bayesian False-Positive Report Probability)
[40,41] may help assess the credibility of association findings. In
the following, we assess the probability of the replicated association
being ‘‘true’’ using a Bayesian approach - PPV [42].
For an association finding, the PPV can be estimated by
PPV~P zjAz ðÞ ~
PA zjz ðÞ P z ðÞ
PA zjz ðÞ P z ðÞ zPA zj{ ðÞ P { ðÞ
~
1{b ðÞ P z ðÞ
1{b ðÞ P z ðÞ zp 1{P z ðÞ ½ 
ð3Þ
where ‘+’ and ‘2’ denote the presence and absence of association,
respectively. A
+ denotes rejection of the null hypothesis (i.e., a
significant association is detected). P(A
+|+)=12b is the statistical
power and P(A
+|2)=p is the type I error rate. P(+) is the
prior (pre-study) probability that the association is true. Similarly,
we can use negative predictive value (NPV) to evaluate the
probability of null hypothesis being true (i.e., no association) when
a follow-up study does not find the association. NPV can be
estimated by
NPV~P {jA{ ðÞ ~
PA {j{ ðÞ P { ðÞ
PA {j{ ðÞ P { ðÞ zPA {jz ðÞ P z ðÞ
~
1{p ðÞ 1{P z ðÞ ½ 
1{p ðÞ 1{P z ðÞ ½  zb:P z ðÞ
ð4Þ
where A{ denotes acceptance of the null hypothesis (i.e., no
association is detected).
Supposing a significant association is identified in the initial
GWA, the probability of the identified association being true is
P1 z ðÞ ~PPV1~P zjAz
1

~
1{b ðÞ P0 z ðÞ
1{b ðÞ P0 z ðÞ zp 1{P0 z ðÞ ½ 
ð5Þ
where P1(+) is the PPV of the initial GWA.
Further suppose that n independent subsequent GWA studies
are performed. If the kth study (k#n) replicates the initial finding
(i.e., the null hypothesis is rejected), the probability of the identified
association being true is
Pk z ðÞ ~PPVk~P zjAz
k

~
1{b ðÞ Pk{1 z ðÞ
1{b ðÞ Pk{1 z ðÞ zp 1{Pk{1 z ðÞ ½ 
ð6Þ
Alternatively, if the kth study does not replicate the initial
finding (i.e., the null hypothesis is accepted), the probability the
association being true is
Pk z ðÞ ~1{NPVk~1{P {jA{
k

~1{
1{p ðÞ 1{Pk{1 z ðÞ ½ 
1{p ðÞ 1{Pk{1 z ðÞ ½  zb:Pk{1 z ðÞ
~
b:Pk{1 z ðÞ
1{p ðÞ 1{Pk{1 z ðÞ ½  zb:Pk{1 z ðÞ
ð7Þ
From Equations 5–7, it can be seen that the probability of a
replicated GWA finding being true is determined by pre-study
prior probability, statistical power, and p value of the test. Note,
here the prior probability changes by incorporating the PPV of
previous studies.
The above Equations are given without considering potential
biases. Here biases refer to those factors (due to study design, data
quality, statistical analysis, or result presentation) that tend to
produce misleading research results. Let’s quantify bias by u - the
proportion of probed analyses that would not have been GWA
findings in an unbiased study, but are nevertheless reported as
such, because of bias [42]. By taking into account bias u, the
probability of an identified association being true can be calculated
as
P1 z ðÞ ~PPV1~P zjAz
1

~
1{bzub ðÞ P0 z ðÞ
1{bzub ðÞ P0 z ðÞ z p 1{u ðÞ zu ½  1{P0 z ðÞ ½ 
ð8Þ
If n independent subsequent GWA studies are performed and
the kth study (k#n) replicates the initial finding, the probability of
the association being true is
Pk z ðÞ ~PPVk~P zjAz
k

~
1{bzub ðÞ Pk{1 z ðÞ
1{bzub ðÞ Pk{1 z ðÞ z p 1{u ðÞ zu ½  1{Pk{1 z ðÞ ½ 
ð9Þ
As a numerical illustration, we assume that a number of
sequential GWA studies are performed using 500 K SNP arrays,
among which 20 SNPs are susceptibility variants. Then the prior
(pre-study) probability of finding at lease one of the susceptibility
variants is P0(+)=20/500,000=4.0610
25, which is quite low
compared to hypothesis-driven studies with prior knowledge or
evidence of the tested association. We next consider an actual
situation where both positive and negative results are involved. We
assume that an initial GWA study identified a significant genotype-
phenotype association, which is followed up by one to six
subsequent independent studies. We show in Table 1 the PPV
values corresponding to various situations where follow-up studies
replicated the initial finding. From Table 1, we can see that if three
among four follow-up studies replicate the initial association and
the fourth does not, the PPV of the identified association is only
,0.31. This means the chance of being true is only 31% and the
chance that this replicated finding is false is still as high as 69%. If
assuming a bias u=0.1, the PPV decreases dramatically to as low
as 0.006. As another example, if four among six follow-up studies
replicate an initial association and two other follow-up studies do
not, the PPV of the identified association is only 0.46. While PPV
GWA Replication
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studies, each non-replicated study may dramatically decrease the
PPV value. The above PPV calculation was based on an
assumption that all the studies have high statistical power of
90%, which is often higher than that achieved in actual studies.
It should be noted that the experiment-wise a level of 0.05 is
used in the above PPV analysis. In GWA studies, to account for
multiple comparison by testing hundreds of thousands SNPs, a
point-wise P value of 10
27 for a genotype-phenotype association is
considered to be statistically significant [11]. However, in PPV
analysis, only the experiment-wise P values that are adjusted for
multiple testing should be used. Otherwise, even point-wise P
values on the order of 10
22–10
25 achieved in an initial GWA can
yield high PPV if directly used in PPV analyses without correction
for multiple testing.
Discussion
Integrating Evidence of Multiple Levels/Sources
By discussing the difficulties of replication, we do not intend to
depreciate the GWA approach and subsequent replication efforts.
This is an evolving area and our understanding of GWA is
improving from the knowledge gained and challenges that remain.
The genetic community has had some useful discussions on design,
implementation, best practice and interpretation of GWA studies
[11]. Even with the difficulty of replication notwithstanding,
variants with relatively large effects may be identified and
replicated in powerful GWA studies [11]. A potential practical
example is the FTO gene, whose association with obesity and
related phenotypes was identified in three independent GWA
studies in French [35], German [36], and British populations [37].
This FTO gene is responsible for 1% of the total heritability of
obesity [43]. Meta-analysis is a useful tool for synthesizing data
and exploring potential heterogeneity [44,45]. Joint (meta) analysis
of data from comparable GWA studies may increase the power of
gene identification when individual GWA studies are underpow-
ered. However, meta-analysis may not always be ideal as it may
suffer from potential problems such as between-study heterogene-
ity and bias (e.g., selective publication) [46].
From systems biology perspective, GWAs are studies at the
DNA level. At best, GWA studies could, in conjunction with fine
mapping efforts, identify the implicated variant(s) at the level of
molecular markers (e.g., SNPs). Although GWA studies may
implicate a gene(s) as a factor contributing to a disease/trait, it
cannot tell anything about how the gene(s) contribute to the
disease/trait. Similarly, bioinformatics tools, while useful, may
only infer some of the functions of the identified markers/genes.
Functional genomic studies, including gene expression studies at
the RNA level and proteomics studies at the protein level, may
provide useful complementary information to GWA studies. For
example, functional genomic studies may unravel critical infor-
mation about the regulation of gene activity under various
conditions that may contribute to our knowledge of molecular
and genetic mechanisms influencing disease development. GWAs,
gene expression and proteomics studies, individually, have shown
some successes in identifying genes for complex diseases. However,
each may be prone to false positive/negative findings, partially due
to multiple testing in genomic approaches, statistical power
(partially associated with conservative procedures accounting for
multiple testing), and the biological complexity of gene expression
and genetic etiology. Gene expression is regulated simultaneously
and interactively at all the three levels, i.e., DNA, RNA, and
protein levels. Gene expression may be regulated at the level of
DNA, RNA, or protein and there is often interaction between
regulatory controls at these different levels. Hence, a genomic
convergence or systems biology based approach that integrates the
information from GWA studies, gene expression and proteomics
may facilitate the identification of key pathways that are globally
involved in the pathogenesis of the disease and/or interactive
factors acting at different levels of disease-gene expression [47]. It
should be noted that genomic convergence may have its own
limitations. Genes identified at the DNA level in GWA studies
may escape confirmation/replication in studies of RNA (micro-
array) or protein (proteomics), partially because of inherent
differences in these experimental approaches and complex
regulation of gene functions involved, even when those genes
actually contribute to disease development.
Gene expression levels can be used as quantitative traits in
traditional linkage or association studies, and the identified loci are
termed expression QTLs (eQTLs) [48]. Given that most common
human diseases are outcome of a complex interaction between
many genetic loci and the environment, there are obvious
advantages to studying the genetics of gene expression in cells
that represent the in vivo state. For example, a recent study
analyzed the expression of 23,720 transcripts in large population-
based blood and adipose tissue cohorts for various obesity related
traits [49]. A core network module in humans and mice was
identified that is enriched for genes involved in the inflammatory
and immune response and was found to be causally associated to
obesity-related traits [49].
Ultimately, the functional relevance of the identified variant(s)
should be confirmed by in vivo or in vitro studies. These functional
studies, however, also face challenges, as results of in vivo and in vitro
Table 1. The PPVs corresponding to various situations where different number of follow-up studies replicated the initial finding.
GWA studies PPV
Initial GWA 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.00072
Replication studies 1 0.012 7.58E-05 7.58E-05 7.58E-05 7.58E-05 7.58E-05 7.58E-05
2 0.189 0.001 7.98E-06 7.98E-06 7.98E-06 7.98E-06 7.98E-06
3 0.807 0.023 0.0001 8.40E-07 8.40E-07 8.40E-07 8.40E-07
4 0.986 0.306 0.002 1.51E-05 8.84E-08 8.84E-08 8.84E-08
5 0.999 0.888 0.044 0.0002 1.59E-06 9.31E-09 9.31E-09
6 0.999 0.993 0.455 0.004 2.86E-05 1.67E-07 9.8E-10
PPV: positive predictive value.
Bold represents the follow-up study that does not replicate the initial finding.
doi:10.1371/journal.pone.0004037.t001
GWA Replication
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models may not necessarily translate into those in humans. How to
best integrate information of multiple levels/sources in gene
identification and functional studies remain a topic for open
discussion. This is an area that requires substantial efforts from
biologists and clinicians, statistical geneticists, bioinformaticians,
and epidemiologists.
In summary, identification of genes underlying human complex
diseases is challenging. Replication, while important and valuable,
is difficult to achieve and may not be sufficient or necessary for
validating GWA findings. Additional information from other lines
of evidence, such as detailed molecular mechanistic studies and
genomic convergence, may be useful for validating and illuminat-
ing the functional relevance of genes identified in GWA studies.
Methods
The power calculation was performed using the ‘‘Genetic Power
Calculator’’ (http://pngu.mgh.harvard.edu/,purcell/gpc/). All
the power calculations in the ‘‘Genetic Power Calculator’’ are
based upon formula derived in Sham et al. [3].
In PPV analysis, the PPV values for various situations were
calculated based on the Bayesian theory. The assumed parameters
were under ideal situations.
Supporting Information
Appendix S1 Determination of marker effect size by QTL effect
size, allele frequency differences, and the LD between marker and
QTL
Found at: doi:10.1371/journal.pone.0004037.s001 (0.08 MB
DOC)
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